Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of OrganonBusiness Wire • 03/30/21
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult Patients with Locally Advanced or Metastatic Urothelial CancerBusiness Wire • 03/30/21
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)Business Wire • 03/29/21
Merck to Hold First-Quarter 2021 Sales and Earnings Conference Call on April 29Business Wire • 03/29/21
Is Merck Stock A Buy As It Teams Up To Produce J&J's Covid Vaccine?Investors Business Daily • 03/26/21
FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) CarcinomaBusiness Wire • 03/23/21